OPKO Health (NASDAQ:OPK) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of OPKO Health (NASDAQ:OPK) in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a $3.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also weighed in on OPK. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday.

OPKO Health Stock Up 0.6 %

Shares of NASDAQ OPK opened at $1.75 on Monday. OPKO Health has a 1 year low of $0.86 and a 1 year high of $1.84. The firm’s 50 day moving average price is $1.55 and its 200 day moving average price is $1.55. The firm has a market cap of $1.19 billion, a P/E ratio of -9.21 and a beta of 1.63. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. As a group, sell-side analysts anticipate that OPKO Health will post -0.25 earnings per share for the current year.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were acquired at an average price of $1.56 per share, with a total value of $780,000.00. Following the purchase, the chief executive officer now owns 212,411,477 shares in the company, valued at approximately $331,361,904.12. The trade was a 0.24 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased a total of 1,389,971 shares of company stock worth $2,124,442 in the last quarter. 47.26% of the stock is owned by insiders.

Institutional Investors Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OPK. Rubric Capital Management LP increased its stake in OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after buying an additional 4,284,336 shares during the period. Millennium Management LLC increased its position in shares of OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after purchasing an additional 2,112,382 shares during the last quarter. Lazard Asset Management LLC increased its position in shares of OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after purchasing an additional 1,502,342 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in shares of OPKO Health in the 4th quarter worth about $2,082,000. Finally, Norges Bank bought a new stake in shares of OPKO Health in the 4th quarter worth about $1,657,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.